09 Sep 2020
Brukinsa (Zanubrutinib; Bruton’s tyrosine kinase (BTK) inhibitor) – BeiGene
CI Scientists Remarks:
Indication | Stage of development |
MCL | Approved |
WM | Filed |
CLL/SLL | Phase 3 |
Marginal Zone Lymphoma (MZL) | Pivotal Phase 2 |
DLBCL | Phase 2 |
Undisclosed B cell malignancies | Phase 1b |
– Dr. Kowndinya, CI Scientists
info@ciscientists.com
For a subscription, please provide your email id